Back to mobile site

Cellectis (CLLS) Reiterated at Market Outperform by Citizens After MRD Clearance

April 14, 2026 5:05 AM EDT Send to a Friend
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $8.00 price target on Cellectis (NASDAQ: CLLS).The analyst commented, "CLLS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login